Reference Citation Analysis: Find an Article, Find a Category, Find a Journal, Find a Scholar

For: Tsuboi K, Yamamoto H, Somura F, Goto H. Successful management of enzyme replacement therapy in related fabry disease patients with severe adverse events by switching from agalsidase Beta (fabrazyme(®)) to agalsidase alfa (replagal (®)). JIMD Rep 2014;15:105-11. [PMID: 24718841 DOI: 10.1007/8904_2014_304] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/02/2013] [Revised: 01/07/2014] [Accepted: 02/19/2014] [Indexed: 01/08/2023] Open

For:	Tsuboi K, Yamamoto H, Somura F, Goto H. Successful management of enzyme replacement therapy in related fabry disease patients with severe adverse events by switching from agalsidase Beta (fabrazyme(®)) to agalsidase alfa (replagal (®)). JIMD Rep 2014;15:105-11. [PMID: 24718841 DOI: 10.1007/8904_2014_304] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/02/2013] [Revised: 01/07/2014] [Accepted: 02/19/2014] [Indexed: 01/08/2023] Open

Number

Cited by Other Article(s)

Pisani A, Riccio E, Sabbatini M. Agalsidase alfa and agalsidase beta in the treatment of Fabry disease: does the dose really matter? Genet Med 2015;17:21-3. [PMID: 25010055 PMCID: PMC4287893 DOI: 10.1038/gim.2014.79] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2014] [Accepted: 05/29/2014] [Indexed: 11/15/2022] Open